Overall survival in patients with metastatic or locally advanced pancreatic cancer following chemoradiation with novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.

• DOI: 10.1200/jco.2023.41.4_suppl.720
• Publication Date: 2023-01-24T21:05:07Z
• Authors: Tara Elisabeth Seery; Chaitali Singh Na...; Phillip D. Reid; Bruno Fang; Heidi Ann McKean; Leonard S. Sender; Sandeep K. Reddy; Patrick Soon-Shiong
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

720 Background: Pancreatic cancer claimed an estimated 47,050 lives in the USA 2020, with expected median overall survival (OS) of 3 months 3rd line. (Manax ASCO GI 2019), no evidence disease control these late stage patients. We hypothesize that effective response against pancreatic requires orchestration both innate and adaptive immune system to accomplish immunogenic cell death benefit. Herein we report updated results fully enrolled cohort a novel combination immunotherapy protocol low-dose chemoradiation, cytokine-induced NK T activation via N-803 (an IL-15 cytokine superagonist ), allogeneic off-the-shelf PDL1-targeted high-affinity (PDL1 t-haNK) infusion. Methods: data from multi-center study, on 83 line or greater, subjects treated low dose, chemo radiation Nab-paclitaxel (100 mg/ m2 IV), Gemcitabine (600 mg/m2 IV); Cyclophosphamide (50 mg PO BID) dose SBRT. This induction immuno-modulation therapy induce DAMPs was followed investigational agents activating systems: Aldoxorubicin (150 N-803, (15 μg/kg SC) PD-L1 t-haNK (~2 × 109cells/dose IV). Prophylactic G-CSF EPO not allowed. All treatments were administered outpatient basis. Results: As submission, follow-up is 4.9 months. Median age 62, M:F ratio 46:36. ECOG 0-1,97%. 74/83 (89%) reported at least 1 product related AE (TRAE) 63/83 (76%) reporting TRA grade higher. The most common anemia 41%, neutropenia 20%, thrombocytopenia 10%, all others <10%. SAEs attributed 8/83 (10%) Treatment ongoing for 6 (7%), 17.1 as longest duration date. OS 5.7 (95% CI: 4.9, 6.4) 26/83 alive PFS 2.3 2.0, 3.6) 37% achieving stable >=8 weeks. rd (N=38) 6.3 months, 4 th greater (N=40) 5.0 Conclusions: Historical month metastatic patients has been exceeded. A doubling seen QUILT 88 investigating PDL1 therapy. Updated will be presented. Clinical trial information: NCT03563144 .